Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Revenue (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Revenue for 12 consecutive years, with $40.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue changed 0.47% year-over-year to $40.6 million, compared with a TTM value of $154.9 million through Dec 2025, up 7.36%, and an annual FY2025 reading of $154.9 million, up 7.36% over the prior year.
  • Revenue was $40.6 million for Q4 2025 at Heron Therapeutics, up from $38.2 million in the prior quarter.
  • Across five years, Revenue topped out at $40.8 million in Q4 2024 and bottomed at $20.0 million in Q1 2021.
  • Average Revenue over 5 years is $31.0 million, with a median of $31.6 million recorded in 2023.
  • The sharpest move saw Revenue dropped 21.19% in 2021, then soared 45.38% in 2022.
  • Year by year, Revenue stood at $20.7 million in 2021, then soared by 45.38% to $30.0 million in 2022, then increased by 14.0% to $34.2 million in 2023, then increased by 19.13% to $40.8 million in 2024, then decreased by 0.47% to $40.6 million in 2025.
  • Business Quant data shows Revenue for HRTX at $40.6 million in Q4 2025, $38.2 million in Q3 2025, and $37.2 million in Q2 2025.